Abstract: The present invention provides methods of detecting a cancer cell in an individual, methods of grading a cancer, and methods of treating a cancer. The methods involve use of functionalized magnetic nanoparticles that comprise a moiety that provides for selective association with, and/or metabolic uptake into, a cancer cell.
Abstract: A unique set of genetic variations associated with lupus are provided. Also provided are methods for detecting such genetic variations and for assessing risk of developing lupus as well as for diagnosing and treating lupus.
Type:
Application
Filed:
May 21, 2008
Publication date:
February 24, 2011
Inventors:
Timothy W. Behrens, Geoffrey Hom, Ward A. Ortmann, Robert R. Graham
Abstract: Provided herein are methods of treating macular degeneration, which comprises administering to a patient in need thereof a therapeutically effective amount of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable salt or solvate thereof.
Abstract: The embodiments set forth herein provide biocompatible self-setting compositions suitable for use in tissue augmentation applications. The biocompatible self-setting compositions described herein exhibit advantageous theological properties and may be applied to a site in the body of a patient by injecting the composition through a 20-30 gauge needle. Once applied to a site in the body, the composition sets to a slow resorbing or substantially non-resorbing matrix. Advantageously, exposure of the composition material to body heat at its site of use enhances setting of the composition.
Abstract: Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
Type:
Grant
Filed:
December 20, 2002
Date of Patent:
February 15, 2011
Assignee:
Umecrine AB
Inventors:
Torbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
Abstract: The present invention relates to methods of gene expression profiling for inflammatory bowel disease pathogenesis, in which the differential expression in a test sample from a mammalian subject of one or more IBD markers relative to a control is determined, wherein the differential expression in the test sample is indicative of an IBD in the mammalian subject from which the test sample was obtained.
Type:
Application
Filed:
July 19, 2010
Publication date:
February 10, 2011
Inventors:
Alexander R. ABBAS, Hilary Clark, Lauri Diehl, Charles Lees, Colin L. Noble, Jack Satsangi
Abstract: Hormone compositions including bioidentical hormones dispersed in a lipid-based cream are provided in syringes for dispensation and self-administration by a user. The compositions, which are topically applied by the user, are percutaneously delivered to the vascular system of the user in accordance with a dosage protocol that causes a rhythmic and cyclic variation in the serum hormone levels that mimics the temporal variation in hormone levels present in the serum of a normal premenopausal woman.
Abstract: This document relates to methods and materials for reducing A?42 levels, reducing A? aggregation, or reducing both A?42 levels and A? aggregation. For example, this document provides methods and materials related to the use of agents (e.g., 5?-cholanic acid) to reduce A?42 levels and to reduce A? aggregation in mammals.
Type:
Application
Filed:
April 28, 2010
Publication date:
January 27, 2011
Inventors:
Todd E. Golde, Abdul H. Fauq, Thomas B. Ladd, Thomas L. Kukar, Craig W. Zwizinski
Abstract: A polymer-surfactant nanoparticle formulation, using the anionic surfactant aerosol OT (AOT) and polysaccharide polymer alginate, is used for sustained release of water-soluble drugs. The AOT-alginate nanoparticles are suitable for encapsulating doxorubicin, verapamil and clonidine, as well as therapeutic agents effective against dermal conditions such as psoriasis. The nanoparticles are also suitable for encapsulating photo-activated compounds such as methylene blue for use in photo-dynamic therapy of cancer and other diseases, and for treating tumor cells that exhibit resistance to at least one chemotherapeutic drug.
Abstract: The invention discloses a steroid compound having the formula (1), wherein dotted bonds represent optional double bonds; R6 is H, ?CH2, or —CH3, or —CH2—CH3; R7 is H, C1-4-alkyl, C2-5 alkenyl or C2-5-alkynyl, wherein the alkyl, alkenyl or alkynyl group may be substituted with 1 to 3 halogen atoms independently chosen from the group of fluorine or chlorine atoms; R11 is H, C1-4-alkyl, C2-4-alkenyl, C2-4-alkynyl or C1-4-alkylidene, wherein the alkyl, alkenyl, alkynyl or alkylidene group may be substituted with 1-3 halogen atoms independently chosen from the group of fluorine or chlorine atoms; E represents together with carbon atoms 16 and 17 of the steroid skeleton a four to seven-membered ring, said ring being ? and in cis-configuration with respect to the steroid skeleton, optionally comprising one or two endocyclic bonds; or a prodrug thereof. Such compounds can be used in therapy and for methods for selective modification of the activity of estrogen receptors.
Abstract: Drug delivery compositions which are suitable for transvaginal administration for the treatment of diseases and disorders of the urogenital tract are described. The drug delivery compositions are administered directly to the vagina using a convenient transvaginal application that deposits a very small volume of drug at the desired site for delivery. This method of administration reduces the systemic levels of the drugs and decreases the side effects which are associated with systemic administration. In the preferred embodiment, the compositions are in the form of a gel. The formulation is administered in volumes of less than or equal to 1 milliliter. In the preferred embodiment, the composition contains an antimuscarinc drug, such as oxybutynin.
Type:
Application
Filed:
July 6, 2009
Publication date:
January 6, 2011
Inventors:
Gerianne Tringali DiPiano, Thomas I. Janicki, Peter Kevin Mays, John Andrew Ziemniak
Abstract: A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing.
Type:
Application
Filed:
September 15, 2010
Publication date:
January 6, 2011
Applicant:
SYNCERA, INC
Inventors:
Tadeusz Z. Wellisz, Timothy C. Fisher, Jonathan K. Armstrong, John Cambridge
Abstract: Treatment protocols for severe psoriasis include administering biologics, stopping all administration of the biologics after the severity of the psoriasis has reduced and has reached an equilibrium, mildness and/or a tolerable state of remission, and administering UV phototherapy. The biologics may include, for example, the biologics found in Amevive®, Enbrel®, Humira®, Raptiva®, and Remicade® and/or alefacept, etanercept, adalimumab, efalizumab, infliximab, and ustekinumab. The UV phototherapy may be repeated, for example daily, weekly, monthly, yearly, to keep the psoriasis in a mild state or in a tolerable state of substantial remission. Parameters for administering UV phototherapy may be determined based on skin tone, Fitzpatrick skin phenotype, the severity of the psoriasis, the area of exposure, and/or the MED.
Abstract: A compound of formula (I): wherein R1 is selected from the group consisting of H, ?-L-Rhamnopyranose, ?-D-Mannopyranose, ?-D-Xylopyranose, ?-D-Glucopyranose, and ?-D-Arabinopyranose; R2 is selected from CH3, COOH, CH2OH, COOCH3 and CH2O-?-D-Arabinopyranose; with the proviso that the compound of formula (I) is not a compound of formula (I) wherein R1 is ?-D-Glucopyranose and R2 is COOH; wherein R1 is ?-L-Rhamnopyranose and R2 is CH3; wherein R1 is ?-D-Glucopyranose and R2 is CH2OH; wherein R1 is ?-D-Xylopyranose and R2 is CH2OH; wherein R1 is ?-L-Rhamnopyranose and R2 is COOCH3, wherein R1 is H and R2 is CH3; wherein R1 is H and R2 is CH2OH; wherein R1 is H and R2 is COOH; or wherein R1 is H and R2 is COOCH3, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
June 17, 2010
Publication date:
December 30, 2010
Inventors:
Andre Pichette, Jean Legault, Charles Gauthier
Abstract: The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).
Abstract: Compound of formula I where X=O or ?N—OH group, R represents a group chosen from A=hydrogen or together with B a carbon-carbon bond, B=hydrogen, hydroxy or together with A a carbon-carbon bond, C, D, E, F=hydrogen or together with D a carbon-carbon bond, or the one of its addition salts with pharmaceutically acceptable acids, with the exception of a few compounds, as a medicament, use in particular as neuroprotectors, novel compounds of formula I and pharmaceutical compositions.
Type:
Grant
Filed:
March 5, 2004
Date of Patent:
December 28, 2010
Assignee:
TROPHOS
Inventors:
Thierry Bordet, Cyrille Drouot, Bruno Buisson
Abstract: The invention concerns a concentrated hormone pharmaceutical composition having from about 0.6 to about 80% of at least one hormone; from about 20 to about 90.4% of at least one solvent, and optionally a pharmaceutically acceptable carrier. The concentrated hormone pharmaceutical composition according to this invention provides a concentrated pharmaceutical composition that is easy to use and saves time and money to the pharmacies dealing with BHRT pharmaceutical products.
Abstract: A personal-care composition in the form of an oil-in-water emulsion is disclosed that provides improved skin feel and effective wrinkle-filling. The personal-care composition comprises a silicone elastomer; a silicone fluid; a combination of particulate materials; a polymeric thickener; and water. The combination comprises at least three particulate materials which pack together in order to fill wrinkles.
Type:
Application
Filed:
June 18, 2010
Publication date:
December 23, 2010
Inventors:
Susan Adair GRIFFITHS-BROPHY, Robert John Elsbrock
Abstract: The present invention relates to a gel composition on alcoholic basis, comprising at least one androgenic steroid and at least one C3-C4 diol as enhancer, as well as the use of a composition comprising at least one androgenic steroid on the scrotum for the treatment and/or prophylaxis of hypogonadism.
Type:
Application
Filed:
June 7, 2010
Publication date:
December 16, 2010
Applicant:
Dr. August Wolff GmbH & Co. Arzneimittel
Abstract: The present invention relates to novel betulinic acid derivatives with increased activity for the treatment of carcinomas and HIV diseases, a method for preparing such novel betulinic acid derivatives as well as their use as pharmaceuticals.
Type:
Grant
Filed:
December 21, 2007
Date of Patent:
December 14, 2010
Assignee:
Novelix Pharmaceuticals, Inc.
Inventors:
Edgar Selzer, Burkhard Jansen, Reinhard Paschke
Abstract: A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X? is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.
Type:
Grant
Filed:
April 20, 2006
Date of Patent:
December 14, 2010
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Inventors:
Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher John Montague Meade, Michel Pairet
Abstract: The present invention relates to methods for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The method and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin aliments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.
Type:
Grant
Filed:
June 23, 2004
Date of Patent:
December 7, 2010
Assignee:
Geron Corporation
Inventors:
Calvin Bruce Harley, Allison C. Chin, Tsutomu Akama, Nancy Yuk-yu Ip, Yung-hou Wong, David M. Miller-Martini
Abstract: The present invention relates to pharmaceutical compositions comprising a ? (1-3) ? (1-4) glucan and a pharmaceutically active agent or a botanical extract. A method to extract and purify cereal ?-glucan is also described. The high purity of the cereal ?-glucan obtained according to the present invention allows for the preparation of clear, colourless viscous liquid preparations. These liquid preparations are stable to gelling effects when kept at ambient temperatures and low ash concentrations, and can be used to prepare the pharmaceutical compositions of the present invention.
Abstract: The presently disclosed subject matter is directed to metallo-oxidoreductase inhibitors having metal binding moities linked to a targeting moiety through a linking group or a direct bond, methods for screening for metallo-oxidoreductase inhibitors, and methods of treating an oxidoreductase related disorder by administering a metallo-oxidoreductase inhibitor to a subject in need of treatment thereof.
Type:
Application
Filed:
November 21, 2007
Publication date:
December 2, 2010
Applicant:
Viamet Pharmaceuticals, Inc.
Inventors:
Robert J. Schotzinger, William J. Hoekstra
Abstract: A process for the preparation of cyclodextrin oligomers or polymers, whereby the cyclodextrin molecules are coupled to one another covalently via a spacer arm, based on a coupling reaction between an alkyne and an azide producing the formation of an aromatic heterocyclic bridge between the coupled units. Also described are the cyclodextrin oligomers or polymers that are obtained and their uses.
Type:
Application
Filed:
October 18, 2007
Publication date:
December 2, 2010
Applicant:
BIOCYDEX
Inventors:
Frederic Turpin, Carole Brigand, Yves Cenatiempo, EI Mustapha Belgsir
Abstract: The invention provides nanodevices or products of manufacture for use as drug delivery vehicles. In one aspect, the invention provides nanodevices or products of manufacture having on-off release mechanisms, e.g., that are “switchable”, or “actuatable” (for example magnetically or ultrasonically switchable), for compounds contained within, e.g., for use as drug delivery nano-vehicles having on-off drug release mechanisms, and their therapeutic applications.
Type:
Application
Filed:
November 14, 2008
Publication date:
December 2, 2010
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Sungho Jin, Seunghan Oh, Karla Brammer, Seong Kong
Abstract: Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.
Abstract: Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.
Abstract: Disclosed herein are compositions that exhibit viscosities suitable for injectable formulations. The compositions comprise bioactive agent-loaded microparticles and hyaluronic acid or a salt thereof in a suitable liquid pharmaceutical carrier. Also disclosed are methods of making and using the compositions.
Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.
Type:
Application
Filed:
February 13, 2008
Publication date:
November 18, 2010
Applicant:
QLT USA, INC.
Inventors:
Eric Dadey, John Middleton, Richard L. Norton
Abstract: The invention provides a hydrogel suitable for use in wound healing, particularly for reducing post-surgical adhesions. The hydrogel comprises cross-linked derivatives of chitosan and dextran polymers. The hydrogel forms when solutions of the polymers are combined.
Type:
Application
Filed:
August 26, 2008
Publication date:
November 18, 2010
Inventors:
Theodore Athanasiadis, Lyall Robert Hanton, Stephen Carl Moratti, Brian Harford Robinson, Simon Rae Robinson, Zheng Shi, James Simpson, Peter John Wormald
Abstract: Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.
Abstract: HIV infection can be detected by measuring phosphorylation levels of the actin-depolymerizing factor (AFD)/cofilin family, and infection can be treated and/or prevented by modulating the HIV co-receptor signaling pathway.
Abstract: A method for preparing porous microparticles containing phytosterol, by preparing a homogeneous melt of phytosterol and a partially water soluble component, cooling the melt to obtain an amorphous solid material, processing the material into a fine powder, and bringing the powder into contact with an aqueous phase under stirring conditions. A composition suitable for preparing a porous microparticle containing phytosterol. A porous microparticle containing phytosterol. A pharmaceutical or food product useful for lowering the cholesterol level in blood.
Abstract: The present invention provides a process for extracting sterols from a high solids, thermochemically hydrolyzed corn fiber using ethanol as the extractant. The process includes obtaining a corn fiber slurry having a moisture content from about 20 weight percent to about 50 weight percent solids (high solids content), thermochemically processing the corn fiber slurry having high solids content of 20 to 50% to produce a hydrolyzed corn fiber slurry, dewatering the hydrolyzed corn fiber slurry to achieve a residual corn fiber having a moisture content from about 30 to 80 weight percent solids, washing the residual corn fiber, dewatering the washed, hydrolyzed corn fiber slurry to achieve a residual corn fiber having a moisture content from about 30 to 80 weight percent solids, and extracting the residual corn fiber with ethanol and separating at least one sterol.
Type:
Grant
Filed:
March 21, 2005
Date of Patent:
November 16, 2010
Assignee:
Archer-Daniels-Midland Company
Inventors:
Charles Abbas, Kyle E. Beery, Thomas P. Binder, Anne M. Rammelsberg
Abstract: A method for making composite excipient particles for use in a pharmaceutical composition comprises a milling step in which particles of an excipient material are milled in the presence of an additive material. The product particles are of small size and the milling requires relatively low input of time and energy. The composite particles are suitable for use in inhalable pharmaceutical compositions.
Type:
Application
Filed:
May 18, 2010
Publication date:
November 11, 2010
Applicant:
Vectura Limited
Inventors:
John Nicholas Staniforth, David Alexander Vodden Morton, Rossella Musa
Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.
Abstract: A solid, implantable dosage form comprising a therapeutically active agent in solid form, optionally with one or more pharmaceutically acceptable excipients, wherein the one or more excipients, when present, do not lead to a significant delay or prolongation of the release of active agent, as compared to an equivalent dosage form containing no excipients when tested in vitro.
Abstract: A pulmonary delivery medicament comprises a plurality of particulates, the particulates comprising a structural matrix and a water insoluble and/or crystalline active agent. The particulates have a geometric diameter of 0.5 to 50 ?m. The water insoluble active agent can be a fungicide, antibiotic, budesonide. A method of making the medicament comprises forming a liquid feedstock, and forming a feedstock suspension by suspending in the liquid feedstock, the active agent and an excipient capable of forming a structural matrix, such as a phospholipid. The feedstock suspension is spray dried to produce the particulates.
Type:
Application
Filed:
May 5, 2010
Publication date:
October 28, 2010
Inventors:
Thomas E. TARARA, Jeffrey G. Weers, Alexey Kabalnov, Ernest G. Schutt, Luis A. Dellamary
Abstract: The invention relates to the use of at least one oxime derivative of cholest-4-en-3-one as antioxidants in the cosmetics and food fields, and as antioxidant preservatives that can be used, in particular, in cosmetic, food and pharmaceutical products.
Abstract: Disclosed herein are implantable medical devices comprising controlled release terpolymers and at least one drug releasable from said terpolymers coating. The terpolymers of the present invention are comprised of acrylate and/or vinyl monomers.
Abstract: The invention relates to a composition containing total triterpenoid sapogenins extracted from bamboo, the preparation method and use thereof. These total triterpenoid sapogenins are extracted from many parts of bamboo such as bamboo shavings in Gramineae by CO2 Supercritical Fluid Extraction technique. In the extract, the content of total triterpenoid sapogenins is 10-90%, while the contents of friedelin and lupenone are 5-35% and 1-10%, respectively. The extract in the invention has good physiological and pharmacological activities such as anti-free radical, anti-oxidation, anti-tumor and anti-hypertension. It can be used in medicines or functional foods for the treatment or prevention of cardiovascular and cerebrovascular diseases and tumor. It is also useful in cosmetics field.
Abstract: Formulations for topical or local administration of drugs directly to the breast or chest to produce a regional or local effect with lower systemic drug levels than when an effective amount is administered systemically are disclosed herein. In a preferred embodiment, the drug is administered to the surface of the breast, areola, or directly to the nipple. The formulations provide increased patient comfort, increased bioavailability and relatively high blood levels in the region to be treated with a reduction of side effects compared to those administered systemically. The preferred formulations contain drugs in the form of micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in the form of a cream, lotion or foam.
Type:
Grant
Filed:
January 2, 2004
Date of Patent:
October 12, 2010
Assignee:
Femmepharma, Inc.
Inventors:
Gerianne T. DiPiano, Peter Kevin Mays, John Ziemniak
Abstract: The invention provides methods, reagents and systems to preferentially mark fast-proliferating cells/tissues (such as cancer), by incorporating non-natural amino acids into proteins, preferably in vivo, using the endogenous protein synthesis machinery of an organism. The incorporated non-natural amino acids contain reactive groups for further chemical reagents, which may serve as a “handle” to for a number of uses, such as imaging of cancer cells, targeting drugs to preferentially kill cancer cells, and proteomic analysis in the context of large scale or high throughput screening for candidate drug leads that affects the proliferation of a target cell, etc.
Type:
Application
Filed:
October 16, 2006
Publication date:
September 30, 2010
Applicant:
California Institute of Technology
Inventors:
David Tirrell, Daniela C. Dieterich, Aaron J. Link, Erin Schuman
Abstract: An inhalable dry powder medicament is provided. The medicament, which provides improved fine particle fraction, may be prepared by (i) fractionating a particulate active ingredient based on aerodynamic particle size, (ii) recovering at least one fraction of the particulate active ingredient and (iii) combining the recovered fraction with a carrier to provide the inhalable dry powder medicament.
Type:
Application
Filed:
July 18, 2008
Publication date:
September 23, 2010
Applicant:
NORTON HEALTHCARE LTD.
Inventors:
Xian-Ming Zeng, Gary Peter Martin, Christoper Marriott, Mohammed Taki
Abstract: The present invention relates to crystalline polymorphs of 3-O-(3?,3?-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine salt (“DSB•2NMG)”), pharmaceutical compositions of the same and use of the same as an active pharmaceutical agent in the treatment of HIV related disorders.
Type:
Grant
Filed:
April 12, 2006
Date of Patent:
September 21, 2010
Assignee:
Myrexis, Inc.
Inventors:
Mike H. O'Neill, Gary G. Sweetapple, Randall M. Walker, Arndt Hausherr, Gunter Koch, David E. Martin
Abstract: A respiratory dispersion is provided for the pulmonary delivery of at least two bioactive agents. The dispersion comprises a propellant suspension medium having dispersed therein a plurality of perforated microstructures, wherein the two bioactive agents are incorporated into individual perforated microstructures.
Type:
Grant
Filed:
February 5, 2008
Date of Patent:
September 7, 2010
Assignee:
Novartis AG
Inventors:
Jeffry G. Weers, Ernest G. Schutt, Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov
Abstract: The present invention relates to the modulation of glucocorticoid metabolism. In particular the invention relates to the modulation of the functional activity of the glucocorticoid receptor by 5? reduced metabolic breakdown products of glucocorticoids.
Abstract: The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules, pharmaceutical compositions comprising those conjugates.
Abstract: A method for providing neuroprotection to a patient in need of neuroprotection, comprising administering a neuroprotective-effective amount of a compound of formula I in which X is an oxygen atom or an ?N—OH group, R is selected from the group consisting of A is a hydrogen atom or together with B a carbon-carbon bond, B is a hydrogen atom, a hydroxy group or together with A a carbon-carbon bond, C is a hydrogen atom or together with D a carbon-carbon bond, D is a hydrogen atom or together with C a carbon-carbon bond, E is a hydrogen atom or together with F a carbon-carbon bond, F is a hydrogen atom or together with E a carbon-carbon bond, or an addition salt with a pharmaceutically acceptable acid.
Type:
Application
Filed:
May 7, 2010
Publication date:
August 26, 2010
Applicant:
TROPHOS
Inventors:
Thierry BORDET, Cyrille Drouot, Bruno Buisson